First Eagle Investments

Napier Park Global Capital is an independent alternative asset management firm founded in 2013 and located in New York City. The firm specializes in alternative credit and structured equity investments, managing approximately $6.7 billion across a diversified range of products. Its offerings include hedge funds, bespoke client separate accounts, private investments, and collateralized loan obligations. Napier Park serves large, sophisticated institutional investors and focuses on providing capital solutions through primary, secondary, and special situations financing. The firm targets various sectors, including healthcare, commercial products, software, restaurants, manufacturing, and space technology, aiming to deliver equity, debt, or hybrid capital for growth, acquisition, or recapitalization opportunities.

QualityMetric is a leader in the development of patient-reported outcome (PRO) and clinical outcomes assessment (COA) products, focusing on the healthcare and life sciences sectors. With over thirty years of experience, the company specializes in standardizing functional health status assessments through scientifically validated surveys that address both general health and specific diseases. QualityMetric employs proprietary methodologies to capture, benchmark, and interpret health outcomes data, providing comprehensive and tailored measurement solutions. Their offerings include a wide range of surveys, advanced analytics, and expert consulting services, aimed at enhancing the understanding of patient health and well-being. By collaborating with leading healthcare and life science companies, QualityMetric plays a vital role in clinical trials and patient surveillance, ultimately contributing to improved healthcare outcomes.

THL Credit is an experienced alternative credit investment manager with $9.5 billion1 of assets under management. Headquartered in Boston, with offices in Chicago, Dallas, Los Angeles and New York, we pride ourselves on having a national presence with a strong regional focus.

Sciens Building Solutions is a provider of fire detection and security services.This includes the design, installation and provision of maintenance services for fire detection and clean agent fire suppression systems in a variety of commercial, institutional, and government facilities.

NewStar Financial, Inc. is a specialized commercial finance company focused on meeting the complex financing needs of companies and private investors in the middle market. The Company specializes in providing a range of senior secured debt financing options to mid-sized companies to fund working capital, growth strategies, acquisitions and recapitalizations, as well as, equipment purchases. NewStar originates loans and leases directly through teams of experienced, senior bankers and marketing officers organized around key industry and market segments.

Wheels Up is a membership-based private aviation company that specializes in on-demand flight services in the United States. By leveraging data and technology, it connects consumers with safety-vetted private aircraft, offering both programmatic and charter options. The company aims to reduce the upfront costs associated with private flying while providing flexibility, service, and safety to its members. Through its mobile app, users can easily book flights, manage accounts, and access ride-share opportunities. Additionally, members participate in the Wheels Down program, which enhances their travel experiences. Wheels Up operates a diverse fleet, utilizing owned, leased, and chartered aircraft to provide a wide range of global travel alternatives.

EUSA Pharma, founded in March 2006 and headquartered in the UK, is a profitable specialty pharmaceutical company that operates globally with a focus on oncology and other critical diseases. The company markets a portfolio of five approved specialty hospital products, including Caphosol®, Xenazine®, Collatamp®, Custodiol®, and Fomepizole®, along with several named-patient products. EUSA Pharma is dedicated to addressing rare diseases and conditions such as oral mucositis, a common side effect of cancer treatments. The company has submitted a Marketing Authorization Application for FOTIVDA (tivozanib HCL) as a first-line therapy for renal cell carcinoma. With plans to expand its portfolio through acquisitions and in-licensing, EUSA Pharma's operations extend across Europe and the USA, supported by a network of commercial partners in Europe, the Middle East, Asia, and Latin America, making its products available in approximately 40 countries worldwide. The company is led by an experienced management team with a strong track record in the specialty pharmaceutical sector.